Advertisement
Canada markets closed

  • S&P/TSX

    24,471.17
    +168.91 (+0.70%)
     

  • S&P 500

    5,815.03
    +34.98 (+0.61%)
     

  • DOW

    42,863.86
    +409.74 (+0.97%)
     

  • CAD/USD

    0.7266
    -0.0011 (-0.16%)
     

  • CRUDE OIL

    75.49
    -0.36 (-0.47%)
     

  • Bitcoin CAD

    86,736.20
    +2,255.20 (+2.67%)
     

  • XRP CAD

    0.75
    +0.01 (+0.89%)
     

  • GOLD FUTURES

    2,674.20
    +34.90 (+1.32%)
     

  • RUSSELL 2000

    2,234.41
    +45.99 (+2.10%)
     

  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     

  • NASDAQ

    18,342.94
    +60.89 (+0.33%)
     

  • VOLATILITY

    20.46
    -0.47 (-2.25%)
     

  • FTSE

    8,253.65
    +15.92 (+0.19%)
     

  • NIKKEI 225

    39,605.80
    +224.91 (+0.57%)
     

  • CAD/EUR

    0.6642
    -0.0011 (-0.17%)
     

Auxly Cannabis Group Second Quarter 2024 Earnings: EPS: CA$0.002 (vs CA$0.013 loss in 2Q 2023)

editorial-team@simplywallst.com (Simply Wall St)
·1 min read

Auxly Cannabis Group (TSE:XLY) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CA$29.2m (up 33% from 2Q 2023).

  • Net income: CA$2.00m (up from CA$12.9m loss in 2Q 2023).

  • Profit margin: 6.9% (up from net loss in 2Q 2023). The move to profitability was primarily driven by higher revenue.

  • EPS: CA$0.002 (up from CA$0.013 loss in 2Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Auxly Cannabis Group shares are up 13% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Auxly Cannabis Group (1 is potentially serious) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.